Table 1.
Subject characteristics of fibroblasts of combined groups and subgroups
| Variable | Control | COPD | P value | Variable | Control (SEO-COPD-matched) | SEO-COPD | P value | Control (older COPD-matched) | Older, mild-moderate COPD | P value |
| Number | 19 | 21 | Number | 9 | 10 | 10 | 11 | |||
| Age, mean years (range) | 61 (42–81) | 62 (44–81) | 0.844 | Age, mean years (range) | 52 (42–59) | 50 (44–55) | 0.349 | 70 (65–81) | 73 (66–81) | 0.176 |
| Male/female, n | 9/10 | 12/9 | 0.548 | Male/female, n | 1/8 | 2/8 | 0.556 | 8/2 | 10/1 | 0.500 |
| Pack-years | 34 (28–40) | 30 (15–50) | 0.627 | Pack-years | 32 (28–35) | 26 (14–30) | 0.673 | 43 (28–51) | 49 (19–53) | 0.823 |
| Stop-months, | 120 (30–240) | 78 (36–96) | 0.337 | Stop-months | 84 (18–168) | 78 (63–93) | 0.677 | 186 (81–252) | 66 (27–96) | 0.421 |
| Non-COPD, n | 19 | – | Non-COPD, n | 9 | – | 10 | – | |||
| COPD, n | – | 21 | COPD, n | – | 10 | – | 11 | |||
| GOLD 1 | – | – | GOLD 1 | – | – | – | – | |||
| GOLD 2 | – | 7 | GOLD 2 | – | – | – | 7 | |||
| GOLD 3 | – | 4 | GOLD 3 | – | – | – | 4 | |||
| GOLD 4 | – | 10 | GOLD 4 | – | 10 | – | – | |||
| FEV1 %pred | 88.1 (82.5–98.0) | 38.8 (17.1–66.7) | 0.000 | FEV1 %pred | 87.0 (83.5–92.0) | 16.5 (14.3–22.7) | 0.000 | 90.7 (82.2–104.0) | 66.7 (43.4–70.5) | 0.000 |
| FVC %pred | 90.3 (83.0–107.5) | 77.9 (44.2–83.5) | 0.005 | FVC %pred | 92.8 (84.6–101.0) | 42.6 (37.9–68.1) | 0.000 | 89.5 (76.7–107.5) | 83.5 (79.7–98.8) | 0.647 |
| FEV1/FVC | 73.6 (71.8–77.7) | 41.8 (28.4–50.0) | 0.000 | FEV1/FVC | 75.9 (73.3–79.0) | 27.6 (26.0–38.5) | 0.000 | 72.1 (70.3–75.1) | 50.0 (41.7–59.0) | 0.000 |
Data are presented as medians with interquartile ranges unless otherwise stated.
Significant differences between groups were tested using Mann–Whitney U tests or unpaired t-tests. P values are stated.
Gold stage based on FEV1 %pred.
%pred, % predicted; SEO, severe, early-onset.